Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Income towards Parent Company of -$7.2 million for Q4 2025, down 2216.75% on a YoY basis from $341077.5 in Q4 2024, and down 302.41% quarter-over-quarter from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Income towards Parent Company for 2 years, with the latest figure at -$7.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company fell 2216.75% year-over-year to -$7.2 million; the trailing twelve-month figure through Dec 2025 stood at -$12.1 million (down 769.64% YoY), and the FY2025 full-year result was -$12.1 million, down 769.64% from the prior year.
  • Income towards Parent Company for Q4 2025 stood at -$7.2 million, down from -$1.8 million in the prior quarter.
  • The five-year high for Income towards Parent Company was -$296473.0 in Q1 2024, with the low at -$7.2 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn
10 Apimeds Pharmaceuticals US 14.47 Mn 10.84 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.22 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -311,633.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00